Rolontis Leads Hanmi’s Global Ambitions As ADVANCE Phase III Endpoint Met
Rolontis, a novel, long-acting granulocyte colony-stimulating factor (G-CSF) licensed out to Spectrum Pharmaceuticals, has become Hanmi Pharmaceuticals' first drug developed with its proprietary platform to approach the regulatory filings stage in global markets.
You may also be interested in...
Biosimilars of Amgen's blockbuster Neulasta pose a competitive threat to long-acting GSF Rolontis, but the company has experience with group purchasing and notes that large oncology clinics will make more revenue by providing higher-priced products.
The ASCO annual meeting will stage an upset in the EGFR field in lung cancer, and competition in breast cancer within the CDK4/6 and PI3 kinase inhibitor classes will get tighter. Loxo could once again steal the show with a tissue-agnostic drug, this time targeting RET.
Hanmi is set to focus on other assets in its innovative drug pipeline after it ends development of novel lung cancer drug olmutinib amid ZAI Lab’s recent cancellation of a licensing agreement with the South Korean pharma.